The present disclosure relates to a method for inhibiting telomerase in cancer cells by means of luterion and, more particularly, to a method for inhibiting telomerase activity in cancer tissues, cancer cells or a cancer patient, the method in which administered are: an anti-cancer composition comprising luterion； a composition for inhibiting telomerase activity in cancer cells； and luterion. Luterion, according to the present disclosure, has the advantage of effectively inhibiting only the proliferation of cancer cells, without affecting normal cells, by inhibiting telomerase activity in cancer cells.
